GMP IPO Watch
WhiteOak Capital Pharma and Healthcare Fund
Direct Plan · Growth Option · WhiteOak Capital Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.04% | +3.52% | 201 of 255 |
| 1M | +2.83% | +1.97% | 97 of 255 |
| 3M | +2.15% | -3.45% | 17 of 252 |
| 6M | +17.50% | +2.92% | 9 of 251 |
| YTD | +24.63% | +1.21% | 8 of 255 |
| 1Y | +20.63% | +1.11% | 13 of 232 |
| 2Y | +15.42% | +2.39% | 10 of 187 |
| INCEPTION | +22.86% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +6.19% | +30.63% | -13.63% | 74% | 30% |
| 6M | +12.25% | +38.22% | -8.72% | 78% | 34% |
| 1Y | +17.97% | +35.54% | +0.61% | 100% | 45% |
| 2Y | +19.79% | +25.73% | +11.12% | 100% | 47% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity90.72%
- Debt3.15%
- Cash6.13%
- Other0.00%
Market Cap Split
- Large Cap29.16%
- Mid Cap22.22%
- Small Cap39.34%
- Others9.28%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 46.25 | 41.94 |
| P/B | 7.40 | 6.29 |
| Price / Sales | 7.35 | 6.05 |
| Price / Cash Flow | 35.06 | 31.26 |
| Dividend Yield (%) | 0.61 | 0.60 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Divis Laboratories | Pharmaceuticals & Biotechnology | 8.36% | -0.09% |
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 7.11% | -0.29% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 6.26% | -0.52% |
| Clearing Corporation of India Ltd | Net Current Assets | 5.55% | — |
| Laurus Labs | Pharmaceuticals & Biotechnology | 3.91% | +0.13% |
| Apollo Hospitals | Equity | 3.75% | -0.98% |
| Cipla | Pharmaceuticals & Biotechnology | 3.68% | +0.43% |
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 3.28% | -0.04% |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 2.88% | +0.22% |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 2.81% | +0.23% |
| Neuland Laboratories | Pharmaceuticals & Biotechnology | 2.60% | -0.28% |
| Dr. Lal Path Labs | Equity | 2.35% | +0.00% |
| Corona Remedies | Pharmaceuticals & Biotechnology | 2.34% | -0.01% |
| Thyrocare Technologies | Equity | 2.27% | -0.04% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 2.09% | -0.12% |
View all 61 holdings
| Ajanta Pharma | Pharmaceuticals & Biotechnology | 2.01% | +0.29% |
| Krishna Institute of Medical Sciences | Equity | 1.85% | -0.07% |
| Max Healthcare Institute | Equity | 1.84% | -1.21% |
| Shaily Engineering Plastics | Consumer Durables | 1.84% | -0.17% |
| Global Health | Equity | 1.82% | -0.10% |
| Narayana Hrudayalaya | Equity | 1.61% | -0.15% |
| Anthem Biosciences | Pharmaceuticals & Biotechnology | 1.57% | -0.11% |
| Vijaya Diagnostic Centre | Equity | 1.56% | -0.03% |
| Onesource Specialty Pharma | Pharmaceuticals & Biotechnology | 1.55% | +0.54% |
| Acutaas Chemicals | Pharmaceuticals & Biotechnology | 1.45% | +0.01% |
| Navin Fluorine International | Chemicals & Petrochemicals | 1.41% | -0.12% |
| Fortis Healthcare | Equity | 1.36% | -0.29% |
| Aarti Pharma Labs | Pharmaceuticals & Biotechnology | 1.20% | +0.10% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 1.20% | — |
| Procter & Gamble Health | Pharmaceuticals & Biotechnology | 1.18% | -0.07% |
| Molbio Diagnostics | Equity | 1.15% | +0.17% |
| Rainbow Childrens Medicare | Equity | 1.15% | -0.12% |
| Piramal Pharma | Pharmaceuticals & Biotechnology | 1.06% | — |
| Aether Industries | Chemicals & Petrochemicals | 1.05% | +0.08% |
| Kovai Medical Center Hospital | Equity | 0.95% | -0.04% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 0.93% | +0.08% |
| Senores Pharmaceuticals | Pharmaceuticals & Biotechnology | 0.80% | -0.05% |
| Jupiter Life Line Hospital | Equity | 0.73% | -0.14% |
| Supriya Lifescience | Pharmaceuticals & Biotechnology | 0.69% | +0.09% |
| Vimta Labs | Equity | 0.67% | -0.06% |
| Innova Captab | Pharmaceuticals & Biotechnology | 0.63% | +0.02% |
| 91TB051126 | Money Market | 0.60% | -0.01% |
| 91TB031226 | Money Market | 0.60% | — |
| Net Receivables / (Payables) | Net Current Assets | 0.58% | — |
| Nephrocare Health Services | Equity | 0.57% | -0.04% |
| 91TB101226 | Money Market | 0.53% | — |
| Manipal Health Enterprises | Equity | 0.52% | -0.63% |
| 182TB51126 | Money Market | 0.47% | -0.01% |
| Sudeep Pharma | Chemicals & Petrochemicals | 0.46% | -0.01% |
| Biocon | Pharmaceuticals & Biotechnology | 0.42% | -0.06% |
| Tatva Chintan Pharma | Chemicals & Petrochemicals | 0.42% | +0.03% |
| Orchid Pharma | Pharmaceuticals & Biotechnology | 0.41% | +0.00% |
| Zota Healthcare | Pharmaceuticals & Biotechnology | 0.40% | +0.06% |
| 91TB291026 | Money Market | 0.37% | +0.00% |
| 91TB191126 | Money Market | 0.32% | -0.01% |
| Novartis | Pharmaceuticals & Biotechnology | 0.24% | — |
| Laxmi Dental | Equity | 0.23% | -0.01% |
| 91TB221026 | Money Market | 0.17% | -0.01% |
| Bharat Parenterals | Pharmaceuticals & Biotechnology | 0.10% | +0.06% |
| 182T121126 | Money Market | 0.08% | +0.00% |
| 364T121126 | Money Market | 0.01% | +0.00% |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 13.80 | 16.32 | Low Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.95 | -0.32 | Above Average |
| 3Y | 1.01 | -0.45 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 2.23 | 0.19 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.00 | 0.96 | Poor Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+59.64% | +47.37% | — | +23.17% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+25.51% | +31.04% | — | +30.18% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+23.57% | — | — | +20.10% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+22.37% | — | — | +11.34% |
|
Mirae Asset Healthcare Fund
Direct Plan · Growth
|
+21.28% | +24.36% | +16.89% | +22.00% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+20.32% | +18.33% | +12.09% | +15.77% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+20.03% | — | — | +11.89% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+18.89% | +19.86% | +8.28% | +8.45% |
|
HDFC Defence Fund
Regular Plan · IDCW Option
|
+18.80% | +34.56% | — | +36.67% |
|
HSBC India Export Opportunities Fund
Direct Plan · Growth
|
+18.74% | — | — | +9.24% |
More From WhiteOak Capital Asset Management Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
WhiteOak Capital Special Opportunities Fund
Direct Plan · Growth Option
|
+9.86% | — | — | +16.53% |
|
WhiteOak Capital Arbitrage Fund
Direct Plan · Growth Option
|
+7.12% | — | — | +7.24% |
|
WhiteOak Capital Multi Asset Allocation Fund
Direct Plan · Growth Option
|
+6.82% | +16.01% | — | +15.30% |
|
WhiteOak Capital Mid Cap Fund
Direct Plan · Growth Option
|
+6.44% | +20.80% | — | +21.53% |
|
WhiteOak Capital Liquid Fund
Direct Plan · Growth Option
|
+6.39% | +6.80% | +6.26% | +5.63% |
|
WhiteOak Capital Ultra Short Term Fund
Direct Plan · Growth Option
|
+6.24% | +6.93% | +6.37% | +5.90% |
|
WhiteOak Capital Equity Savings Fund
Direct Plan · Growth Option
|
+5.27% | — | — | +10.73% |
|
WhiteOak Capital Multi Cap Fund
Direct Plan · Growth Option
|
+2.50% | +18.14% | — | +17.57% |
|
WhiteOak Capital Balanced Advantage Fund
Direct Plan · Growth Option
|
+1.98% | +11.98% | — | +12.76% |
|
WhiteOak Capital Balanced Hybrid Fund
Direct Plan · Growth Option
|
+1.54% | +11.10% | — | +11.27% |
About This Scheme
Investment Objective
To provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved.
Stated Asset Allocation
Equity & Equity related Instruments of Pharma and Healthcare companies: 80% - 100%; Equity and Equity Related Instruments companies (including REITs) other than above: 0% - 20%; Money Market Instruments##, Other Liquid Instruments^, Gold and Silver ETFs and units of Domestic Mutual Fund Schemes@: 0% - 20%; Units issued by InvITs: 0% - 10% ##Money market instruments include commercial papers, commercial bills, treasury bills, Government securities having an unexpired maturity up to one year, call or notice money, certificate of deposit, usance bills, and any other like instruments as specified by the Reserve Bank of India. ^Other liquid instruments shall include cash, bank deposits with Scheduled Commercial Banks, Government Securities, Treasury bills, Repo on Government securities and any other instruments as specified by SEBI. @Units of domestic mutual fund schemes are permitted only in Overnight funds, Liquid funds and Money Market funds. As per Para 3.8.1.c of SEBI Master Circular on Mutual Funds dated March 20, 2026, the Scheme will invest residual portion in equity and equity related instruments, money market instruments and other liquid instruments, gold and silver instruments (ETFs) as permitted by SEBI and in InvITs, subject to the ceilings laid out in SEBI (Mutual Fund) Regulations, 2026 with respect to the respective asset class.
Exit Load
Nil
Fund Managers
FM1 - Mr. Ramesh Mantri; FM2- Mr. Piyush Baranwal; FM3 - Mr. Dheeresh Pathak ; FM4 - Mr. Ashish Agrawal; FM5 - Ms. Trupti Agrawal
FM1 - Comanage/Equity; FM2 - Comanage/Debt; FM3 - Assistant Fund Manager - Equity; FM4 - Fund Manager - Arbitrage Transactions; FM5 - Assistant Fund Manager - Equity
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.